BREAST CANCER IN A PATIENT DURING LACTATION (CLINICAL CASE)
Main Article Content
Abstract
Breast cancer (BC) diagnosed during lactation is a complex medical and social problem. This disease belongs to the broader group of so-called «gestational» or «pregnancy-associated» cancers, which includes cases detected during pregnancy, in the first year after childbirth, and during any period of breastfeeding. Given the trend towards late childbearing in developed countries, the incidence of this condition is increasing and ranges from 15 to 35 cases per 100000 births, according to various sources. The average age of patients is around 33 years.
The complexity of managing such patients is due to physiological changes in the mammary gland, which mask the symptoms, the aggressive course of the tumor process, and the need to consider the interests of both the mother and the child. In this article, we will explore the clinical features, diagnosis, and current approaches to the treatment of breast cancer during lactation, based on the latest scientific evidence.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
1. Papatheodoridi A, Papamattheou E, Marinopoulos S, Ntanasis-Stathopoulos I, Dimitrakakis C, Giannos A, et al. Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature. Med Sci (Basel). 2023; 11(2): 35. doi: 10.3390/medsci11020035
2. Al-Awadhi A, Alnaqbi S, Albawardi A. Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature. Cureus. 2024; 16(2): e53419. doi: 10.7759/cureus.53419
3. Ladwa A, Elghawy O, Schroen A, Abernathy K, Schlefman J, Dillon P. Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab. Case Rep Oncol. 2023; 16(1): 1129-1135. doi: 10.1159/000534146
4. Lee JH, Ryu JM, Lee SK, Chae BJ, Lee JE, Kim SW, et al. Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis. Cancers (Basel). 2023; 15(5): 1556. doi: 10.3390/cancers15051556
5. Ismail Y, Zakaria AS, Allam R, Götte M, Ibrahim SA, Hassan H. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer. Pathol Res Pract. 2024; 253: 154994. doi: 10.1016/j.prp.2023.154994
6. Zhang M, Yuan J, Wang M, Zhang M, Chen H. Chemotherapy is of prognostic significance to metaplastic breast cancer. Sci Rep. 2024; 14(1): 1210. doi: 10.1038/s41598-024-51627-1